Stan Yakatan
Stan
Yakatan is Chairman and Cofounder of
Katan Associates.
After 30 years as a successful CEO, entrepreneur, and operational
manager, Stan has dedicated the last 12 years of his career to
sharing his experiences with management teams interested in building
technology based companies. His experience as a “C” level executive is
far reaching and he has served in such a capacity with:
- New England Nuclear
- EI Dupont
- ICN Pharma
- New Brunswick Scientific
- Biosearch
Stan has founded or cofounded in excess of 15 companies in the United States, Canada, Israel, France, and Germany. In many cases he has also served as the initial CEO, and Chairman of these companies. In his career, he has advised several of the world’s leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA), and Biocapital (Canada). During the 1990s Biocapital was the most successful venture capital fund in Canada.
Stan currently serves in a business development capacity for the XL TechGroup (AIM: XLT). The XL Tech Group systematically discovers unmet business needs, then creates, selects, and develops new technology businesses, and scales them to liquidity. He assisted XL TechGroup in the development of its business model, and advised on the overall capitalization strategy for XL Tech Group. In October 2004, XL TechGroup undertook an Initial Public Offering in connection with its listing on the Alternative Investment Market (“AIM”), raising in excess of $40 million.
He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1 billion in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, “Capital Raising for the Technology-Based Startup” and “The Need to be Global in the Quest for Capital and Partners”. Rick Biondi, Editor of Lab Business Magazine stated,”Mr. Yakatan is a venture capital raising guru and it is part of his genetic make-up.”
Stan is currently the Chairman of Grant Life Sciences, Inc. (OTCBB:GLIF), a company developing a revolutionary test for the screening of cervical cancer. He is also a member of the Board of Directors of Biophan, Inc. (OTC.BB). He serves as the strategic advisor to the State Government of Victoria, Australia. He is also the Executive Director and Chairman of Biocomm, in Melbourne, Australia, the first of its kind regional business development agency and early-stage capital pool. He currently sits on the Board of Mercury Therapeutics, Inc. which is developing new drugs for diabetes and obesity, and Phenomenome Discoveries, Inc., a novel biomarker company.
Read his LinkedIn profile. Visit his Facebook page.
